ECEESPE2025 ePoster Presentations Growth Axis and Syndromes (132 abstracts)
GH therapy and its short-term effectiveness in hong kong (the growth study)
Antony Fu 1 , Malika Alimussina 2 , Jillian Bryce 2 , Minglu Chen 2 , Sanhita Koley 2 , Jessica Anderson 2 , Ting Ting Chen 3 , Kate Chan 3 , Suki Suk Yan Chan 4 , Kent Ho-chung Yau 5 , Jacky Chung 6 , Sammy Wong 7 , Eunice Wong 8 , Winnie Yuen 9 , Suet Ching Chen 2 & Faisal Ahmed 2
1Princess Margaret Hospital, Hong Kong, The Chinese University of Hong Kong, Paediatric and Adolescent Medicine, Hong Kong, Hong Kong; 2University of Glasgow, Glasgow, United Kingdom; 3Chinese University of Hong Kong, Hong Kong, Hong Kong; 4Prince of Wales Hospital, Hong Kong, Hong Kong; 5Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong; 6Caritas Medical Centre, Hong Kong, Hong Kong; 7Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong; 8Tuen Mun Hospital, Hong Kong, Hong Kong; 9Kwong Wah Hospital, Hong Kong, Hong Kong
JOINT1385
Background: To understand the use of recombinant human growth hormone (GH) therapy (rhGH) in Hong Kong, six paediatric centres in Hong Kong have used the GloBE-Reg platform to systematically collect data on rhGH in children and adolescents.
Methods: A descriptive and comparative analysis of retrospective data of local patients treated with rhGH on GloBE-Reg (https://globe-reg.net/). Anthropometric measurements were converted into standard deviation scores (SDS) using local reference data. Baseline height SDS (HtSDS) and first-year response to rhGH, including delta HtSDS, were calculated.
Results: Of the 294 cases in the registry, baseline and first-year data were available for 261(89%) (M:F, 126:135). All cases received daily rhGH. Among these 261, 107 (41%) had GH deficiency (GHD), with rhGH initiated at a median age of 10.9yrs (10th, 90th centiles, 5.9, 14.3). The median HtSDS increased from -3.2 (-4.2, 1.9) at baseline to -2.7 (-3.8, 1.4) after one year, with a median delta HtSDS of 0.4(-0.1, 1.1). A total of 47 (18%) cases received rhGH for idiopathic short stature, with therapy initiated at a median age of 11.0yrs (5.6, 13.9). Over the first year, the median HtSDS increased from -2.9 (-4.1, -2) to -2.4 (-3.5, -1.8), with a median delta HtSDS of 0.5 (0.2, 1.1). Among the 46 (18%) patients with Turner syndrome, rhGH was initiated at a median age of 10.6yrs (4.4, 14.7). The median baseline HtSDS was -3.5 (-4.5, -2.6), increasing to -3.0 (-4.2, -2) after one year, with a median delta HtSDS of 0.5 (0.03, 0.9). In the 15 (6%) patients with Prader-Willi syndrome, rhGH commenced at a median age of 3.8yrs (1.1, 13.1). The median baseline HtSDS was -1.8 (-3.5, -0.4), improving to -1.4 (-2.4, 0.3) after one year, with a median deltaHtSDS of 0.8 (-0.2, 1.3). In the 19 (7%) cases classified as "Other Disorders” who did not have a clear rhGH indication, rhGH was initiated at a median age of 9.6yrs (4.4, 10.7). The median baseline HtSDS reduced from -0.3 (-3.7, 2.5) to -0.7 (-3.1, 2.2) over the first year, with a median delta HtSDS of -0.3 (-0.6, 0.8). Compared to the GHD group, the median first-year delta HtSDS was significantly lower in the "Other Disorders" group (P <0.0001).
Conclusion: This is the first study to characterize the local treatment landscape of rhGH in children and adolescents. The observed heterogeneity in treatment response in Hong Kong requires further analysis so that clinical effectiveness can be optimised.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more